Edition:
United States

Eli Lilly and Co (LLY.F)

LLY.F on Frankfurt Stock Exchange

72.86EUR
20 Jul 2017
Change (% chg)

€0.57 (+0.79%)
Prev Close
€72.30
Open
€72.86
Day's High
€72.86
Day's Low
€72.86
Volume
0
Avg. Vol
1,301
52-wk High
€81.75
52-wk Low
€59.00

Latest Key Developments (Source: Significant Developments)

Adimab says entered into agreement to transfer adimab platform to Lilly
Tuesday, 18 Jul 2017 09:00am EDT 

July 18 (Reuters) - Eli Lilly And Co :Adimab - entered into agreement with Eli Lilly to transfer Adimab platform to Lilly for discovery & optimization of antibody-based drugs in therapeutic areas.  Full Article

Eli lilly reaches settlement agreement in U.S. Cialis patent litigation
Wednesday, 12 Jul 2017 10:00am EDT 

July 12 (Reuters) - Eli Lilly And Co ::Lilly reaches settlement agreement in U.S. Cialis patent litigation.Says as part of agreement, Cialis exclusivity is now expected to end at earliest on September 27, 2018..Says ‍as part of agreement, cialis exclusivity is now expected to end at earliest on September 27, 2018.​.Says no change to company's 2017 financial guidance or mid-term expectations through remainder of decade as a result of this settlement​.Says there will be no change to company's 2017 financial guidance or mid-term expectations through remainder of decade as a result of this settlement.Says patent expiration for Adcirca still expected on Nov. 21, or on May 21, 2018, if U.S. FDA grants co's application for pediatric exclusivity.  Full Article

UK Supreme Court confirms ruling on Lilly's patent case
Wednesday, 12 Jul 2017 05:14am EDT 

July 12 (Reuters) - Eli Lilly And Co :UK Supreme Court confirms that products by Actavis would infringe Lilly's patent, dismisses Actavis' cross-appeal.  Full Article

FDA grants priority review for Lilly's abemaciclib
Monday, 10 Jul 2017 06:45am EDT 

July 10 (Reuters) - Eli Lilly And Co ::FDA grants priority review for Lilly's abemaciclib for the treatment of advanced breast cancer.Eli Lilly And Co - ‍lilly intends to submit abemaciclib to European regulators in Q3 of 2017 and to Japanese regulators before end of 2017​.Eli Lilly And Co - ‍working closely with fda and anticipates agency action on the application in Q1 of 2018 for abemaciclib​.  Full Article

UK Supreme Court rules in Lilly's favor on Alimta vitamin regimen patents
Friday, 7 Jul 2017 07:45am EDT 

July 7 (Reuters) - Eli Lilly And Co :UK Supreme Court rules in Lilly's favor on alimta vitamin regimen patents.Eli Lilly and Co - UK Supreme Court also affirmed indirect infringement finding by UK Court of appeal.Eli Lilly and Co - ‍ruling came in case of Actavis V. Eli Lilly and Company​.Says full judgment is scheduled to be handed down on Wednesday, July 12, 2017.Eli Lilly - Litigation relating to alternative salt forms of Alimta that Actavis's products infringe co's vitamin regimen patents in UK, France, Italy,Spain.  Full Article

Lilly and Purdue University announce strategic research collaboration
Thursday, 6 Jul 2017 08:00am EDT 

July 6 (Reuters) - Eli Lilly And Co :Lilly and Purdue University announce strategic research collaboration.‍Five-year agreement, where Lilly will provide up to $52 million, marks purdue's largest strategic collaboration with a single company​.  Full Article

Incyte says Japan Ministry of Health, Labor And Welfare grants marketing approval for Olumiant
Monday, 3 Jul 2017 08:00am EDT 

July 3 (Reuters) - Incyte Corp :Japan ministry of health, labor and welfare (mhlw) grants marketing approval for olumiant® (baricitinib) for the treatment of rheumatoid arthritis.Incyte- ‍japan marketing authorization of olumiant triggers $15 million milestone payment from lilly to co, which co expects to recognize, in full,in q3 2017​.  Full Article

Eli Lilly and Co sets quarterly dividend of $0.52 per share
Monday, 19 Jun 2017 01:05pm EDT 

June 19 (Reuters) - Eli Lilly And Co :Sets quarterly dividend of $0.52per share.  Full Article

Eli Lilly files supplemental biologics license application with FDA for Taltz
Thursday, 15 Jun 2017 10:35am EDT 

June 15 (Reuters) - Eli Lilly And Co :Eular 2017: Lilly's Taltz (ixekizumab) demonstrated significant improvements in disease signs and symptoms at 24 weeks among patients with active psoriatic arthritis who had prior inadequate response or intolerance to TNF inhibitors.Eli Lilly and Co - Lilly has filed a supplemental biologics license application with FDA for Taltz as a treatment of adult patients with active PSA.Eli Lilly - patients treated with either dosing regimen of Taltz experienced significant improvements compared with placebo in other key secondary measures.Eli Lilly and Co - submissions to other regulatory agencies around world are expected later in the year for Taltz.Eli Lilly and Co- serious adverse events and discontinuation rates due to adverse events were not significantly different between treatment groups.Incidence of treatment-emergent adverse events was greater with Taltz treatment compared with placebo.Taltz is also in Phase 3 trials for treatment of radiographic and non-radiographic axial spondyloarthritis.  Full Article

Lilly says Jardiance tablets to be studied in chronic kidney disease
Monday, 12 Jun 2017 08:00am EDT 

June 12 (Reuters) - Eli Lilly And Co ::Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease.Says plans to conduct a new, large clinical outcomes trial investigating Jardiance along with Boehringer Ingelheim.Eli Lilly And Co - ‍trial will enroll people with chronic kidney disease both with and without type 2 diabetes​.Says trial will enroll people with chronic kidney disease both with and without type 2 diabetes.Eli Lilly - ‍boehringer Ingelheim, co announced plans to conduct new, large clinical outcomes trial investigating Jardiance tablets.  Full Article

BRIEF-Eli Lilly and Co sets quarterly dividend of $0.52 per share

* Sets quarterly dividend of $0.52per share Source text for Eikon: Further company coverage: